Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 1,000 Shares of Stock

Key Points

• Enliven Therapeutics CEO Samuel Kintz sold 1,000 shares of stock on September 19th for a total of $20,250, resulting in a 0.11% decrease in his ownership.
• The company's stock price fell by $0.96 during midday trading, closing at $18.96, with significant trading volume of 2,310,053 shares.
• Analysts have given Enliven Therapeutics an average Buy rating with a target price of $41.20, notably with recent upgrades from HC Wainwright and Robert W. Baird.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 1,000 shares of the company's stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $20.25, for a total value of $20,250.00. Following the sale, the chief executive officer owned 921,892 shares of the company's stock, valued at $18,668,313. This represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total value of $95,450.00.
• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.00, for a total value of $11,800.00.
• On Monday, August 18th, Samuel Kintz sold 10,393 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.02, for a total value of $208,067.86.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $281,500.00.

Enliven Therapeutics Stock Performance

Shares of ELVN stock traded up $0.96 during trading hours on Monday, reaching $19.92. The company had a trading volume of 423,260 shares, compared to its average volume of 597,869. Enliven Therapeutics, Inc. has a twelve month low of $13.30 and a twelve month high of $30.03. The company has a market capitalization of $1.18 billion, a P/E ratio of -9.96 and a beta of 0.88. The stock's fifty day simple moving average is $20.05 and its 200 day simple moving average is $19.64.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 target price for the company. Robert W. Baird increased their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Finally, HC Wainwright raised their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Wednesday, July 2nd. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Enliven Therapeutics has an average rating of "Buy" and a consensus target price of $41.20.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after buying an additional 2,630 shares during the last quarter. Quantbot Technologies LP bought a new position in Enliven Therapeutics during the 1st quarter worth approximately $60,000. BNP Paribas Financial Markets lifted its holdings in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after buying an additional 930 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after buying an additional 3,490 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its holdings in Enliven Therapeutics by 58.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company's stock worth $136,000 after buying an additional 2,500 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.